P44 p42 map kinase antibodies

Collagen was purchased from Takeda Austria GmbH (Linz, Austria). Rivaroxaban and edoxaban were kindly provided by Bayer Vital GmbH (Leverkusen, Germany) and Daiichi Sankyo Co., Ltd. (Tokyo, Japan), respectively. Phospho-specific p44/p42 MAP kinase antibodies, p44/p42 MAP kinase antibodies, phospho-specific HSP27 antibodies (Ser-78) and phospho-specific HSP27 antibodies (Ser-82) were purchased from Cell Signaling Technology, Inc. (Beverly, MA). HSP27 antibodies and GAPDH antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The PDGF-AB enzyme-linked immunosorbent assay (ELISA) kit was obtained from R&D System, Inc. (Minneapolis, MN). The phosphorylated HSP27 ELISA kit was purchased from Enzo Life Science INC. (Farmingdale, NY). ECL Western blotting detection system was obtained from GE Healthcare (Buckinghamshire, UK). Other materials were obtained from commercial sources.

PGF2α was obtained from Sigma-Aldrich Co. (St. Louis, MO, USA). The ELISA kits for mouse IL-6 and mouse VEGF were purchased from R&D Systems, Inc. (Minneapolis, MN, USA). Phospho-specific p44/p42 MAP kinase antibodies, p44/p42 MAP kinase antibodies, phospho-specific p38 MAP kinase antibodies, and p38 MAP kinase antibodies were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). An ECL Western blotting detection system was obtained from GE Healthcare Life Sciences (Buckinghamshire, UK). Negative control-small interfering RNA (siRNA) (Silencer Negative Control #1 siRNA (Neg)) and HSP22-siRNA (s206904 (#1) and s96094 (#2)) were purchased from Ambion (Austin, TX, USA). Other materials and chemicals were obtained from commercial sources.